ClinicalTrials.gg
CompletedNCT01967940Updated Nov 16, 2018Results posted

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

A Phase 3 interventional study of TAF and Placebo in HIV, HIV Infections and Acquired Immunodeficiency Syndrome, sponsored by Gilead Sciences. Completed at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Primary conditionAcquired Immunodeficiency SyndromeRegistry: HIV InfectionsReclassifiedWhy we changed it
Registry
HIV Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Acquired Immunodeficiency Syndrome
Why
  1. The study's listed conditions name Acquired Immunodeficiency Syndrome, a narrower term within HIV Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. tenofovir alafenamide · Acquired Immunodeficiency Syndrome.

Enrollment
15th of 21
55 · median 80
Started
2013
with 2 others
Phase 3
6 of 21
none open now
Registered
5th of 21
by date
Lead sponsor
6 of 21
Gilead Sciences

Among the 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome, this one is the 15th largest by enrollment, is one of 3 that started in 2013, is one of 6 in phase 3, and was the 5th registered.

Acquired Immunodeficiency Syndrome

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

1 of the 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About tenofovir alafenamide

tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of tenofovir alafenamide (TAF) versus placebo, each administered with the existing, failing antiretroviral (ARV) regimen. There are 2 parts to this study: Part 1 and Part 2.

Part 1 consists of 2 cohorts, starting with a sentinel cohort, in which participants will be enrolled to receive open-label TAF in addition to their current failing ARV regimen. This cohort will then be followed by a randomized, double-blind, cohort to compare the addition of TAF or placebo in HIV-1 positive adults who are failing their current ARV regimen.

In Part 2, all participants who complete Part 1 of the study will discontinue their failing ARV regimen and TAF or placebo for a 14-day washout period. Following the washout period, all participants who received TAF in Part 1 and have a > 0.5 log10 decline in HIV-1 RNA will receive elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single-tablet regimen (STR) plus atazanavir (ATV) once daily for 48 weeks. Participants who received TAF who have a ≤ 0.5 log10 decline in HIV-1 RNA will be discontinued from the study and will not be eligible to continue into Part 2 of the study. All participants who received placebo in Part 1 will be eligible to participate in Part 2 regardless of their viral load change. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.

03

Conditions studied

  • HIV
  • HIV Infections
  • Acquired Immunodeficiency Syndrome

Browse trials for

Keywords

  • HIV-1
  • HIV
  • Treatment-Experienced
04

In context

Acquired Immunodeficiency Syndrome Reclassified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.

This study's enrollment of 55 is below the median of 96 across 2,252 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability to understand and sign a written form, which must be obtained prior to initiation of study procedures
  • Currently taking a failing ARV regimen
  • Plasma -1 RNA ≥ 500 copies/mL but ≤ 100,000 copies/mL at screening
  • Normal
  • Estimated (eGFR) ≥ 50 mL/min according to the formula for creatinine clearance
  • (AST)/aspartate aminotransferase (AST) ≤ 5 × the (ULN)
  • Total ≤ 1.5 mg/dL, or normal direct bilirubin
  • Adequate hematologic function
  • Serum amylase ≤ 5 × ULN
  • Females may enter the study if it is confirmed that she is:

    • Not pregnant or nursing
    • Of non- (ie, have had a hysterectomy, both ovaries removed, medically documented ovarian failure, or are women > 54 years of age with cessation [for ≥ 12 months] of previously occurring menses), or
    • Of childbearing potential and agrees to utilize highly effective methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following study drug dosing

      • Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing.
  • Males must agree to utilize a highly effective method of contraception during heterosexual intercourse or be non-heterosexually active, or practice sexual abstinence from first dose throughout the study period and for 30 days following the last study drug dose.
  • Males must agree to refrain from sperm donation from first dose until at least 30 days after the last study drug dose.

Key Exclusion Criteria:

  • A new AIDS-defining condition diagnosed within the 30 days prior to screening
  • surface antigen (HBsAg) positive
  • antibody positive (individuals with positive hepatitis C virus (HCV) antibody and without detectable HCV RNA are permitted to enroll)
  • History of integrase inhibitor use
  • Screening or historical genotype reports shows Q151M or T69ins or more than 3 TAMs.
  • Screening or historical genotype report shows resistance to integrase inhibitors
  • Individuals experiencing decompensated cirrhosis
  • Current alcohol or substance use
  • History of within the past 5 years (prior to screening) or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma. Individuals with cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of Part 1, Day 1 and must not be anticipated to require systemic therapy during the study.
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Part 1, Day 1
  • Any other clinical condition or prior therapy that would make the individual unsuitable for the study or unable to comply with dosing requirements
  • Participation in any other clinical trial (including observational trials) without prior approval from the sponsor is prohibited while participating in this trial
  • Receiving ongoing therapy with any disallowed medications, including any drugs not to be used with elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide or known allergies to the of E/C/F/TAF STR

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Part 1 Sentinel Cohort (TAF)

    TAF + their current failing ARV regimen for 10 days in Part 1

    Drug: TAF · Drug: Current failing ARV regimen

  • Experimental
    Part 1 Randomized Cohort (TAF)

    Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive TAF + their current failing ARV regimen for 10 days in Part 1.

    Drug: TAF · Drug: Current failing ARV regimen

  • Placebo comparator
    Part 1 Randomized Cohort (Placebo)

    Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive placebo + their current failing ARV regimen for 10 days in Part 1.

    Drug: Placebo · Drug: Current failing ARV regimen

  • Experimental
    Part 2 E/C/F/TAF+ATV

    Following a 14-day period to confirm eligibility, participants in the Randomized Cohort TAF group with a \> 0.5 log10 decline in HIV-1 RNA and all participants completing the Randomized Cohort Placebo group will receive E/C/F/TAF+ATV for 48 weeks in Part 2. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.

    Drug: E/C/F/TAF · Drug: ATV

Interventions

  • DrugTAF

    25 mg tablet administered orally once daily with food

    Also known as: Vemlidy®, GS-7340

  • DrugPlacebo

    Tablets to match TAF administered orally once daily with food

  • DrugE/C/F/TAF

    Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

    150/150/200/10 mg STR administered orally once daily with food

    Also known as: Genvoya®

  • DrugCurrent failing ARV regimen

    Participants will continue taking their current ARV regimen as prescribed in Part 1.

  • DrugATV

    300 mg tablet administered orally once daily.

    Also known as: Reyataz®

07

What researchers measure

Primary outcomes

  1. Part 1: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 10

    Time frame: Day 10

Secondary outcomes

  1. Part 1: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Day 10

    Time frame: Baseline; Day 10

  2. Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 24

    Time frame: Up to Week 24

  3. Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 48

    Time frame: Up to Week 48

  4. Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 24

    Time frame: Up to Week 24

  5. Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 48

    Time frame: Up to Week 48

  6. Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  7. Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 48

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  8. Part 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24

    The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  9. Part 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 48

    The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  10. Part 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 24

    Time frame: Baseline; Week 24

  11. Part 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 48

    Time frame: Baseline; Week 48

  12. Part 2: Change From Baseline in CD4+ Cell Count at Week 24

    Time frame: Baseline; Week 24

  13. Part 2: Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48

  14. Part 2: Change From Baseline in CD4+ Percentage at Week 24

    Time frame: Baseline; Week 24

  15. Part 2: Change From Baseline in CD4+ Percentage at Week 48

    Time frame: Baseline; Week 48

08

Results

Posted Jun 12, 2017

Participant flow

Participants were enrolled at study sites in the United States, Uganda, Thailand, Russian Federation, and Dominican Republic. The first participant was screened on 25 October 2013. The last study visit occurred on 31 July 2017.

Part 1
Participant flow — Part 1
MilestonePart 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort PlaceboPart 2 E/C/F/TAF + ATV
Started1228150
Completed1228150
Not completed0000
Part 2
Participant flow — Part 2
MilestonePart 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort PlaceboPart 2 E/C/F/TAF + ATV
Started00038
Completed00035
Not completed0003
Withdrew: Enrolled in part 2 and never treated0001
Withdrew: Adverse event0001
Withdrew: Unknown reason0001

Outcome measures

PrimaryPart 1: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 10
Time frame:
Day 10
Reported as:
Number · percentage of participants
Part 1: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 10
percentage of participantsPart 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort Placebo
Part 1: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 1058.360.70
Statistical analysis
  • Part 1 Randomized Cohort TAF vs Part 1 Randomized Cohort Placebo · Fisher Exact · p = <0.001 · Difference in proportions: 60.7 · 95% CI 42.6 to 78.8The 95% confidence interval was estimated based on unconditional exact method using 2 inverted 1-sided tests with the standardized statistic.
SecondaryPart 1: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Day 10
Time frame:
Baseline; Day 10
Reported as:
Mean · log10 copies/mL
Part 1: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Day 10
log10 copies/mLPart 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort Placebo
Part 1: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Day 10-0.72 ± 0.574-0.70 ± 0.628-0.04 ± 0.233
SecondaryPart 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 24
Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 24
percentage of participantsPart 2 E/C/F/TAF + ATV
Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 2437.8
SecondaryPart 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 48
Time frame:
Up to Week 48
Reported as:
Number · percentage of participants
Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 48
percentage of participantsPart 2 E/C/F/TAF + ATV
Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 4848.6
SecondaryPart 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 24
Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 24
percentage of participantsPart 2 E/C/F/TAF + ATV
Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 2475.7
SecondaryPart 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 48
Time frame:
Up to Week 48
Reported as:
Number · percentage of participants
Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 48
percentage of participantsPart 2 E/C/F/TAF + ATV
Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 4881.1
SecondaryPart 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24
percentage of participantsPart 2 E/C/F/TAF + ATV
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 2486.5
SecondaryPart 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 48

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 48
percentage of participantsPart 2 E/C/F/TAF + ATV
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 4897.3
SecondaryPart 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24

The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24
percentage of participantsPart 2 E/C/F/TAF + ATV
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 2494.6
SecondaryPart 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 48

The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 48
percentage of participantsPart 2 E/C/F/TAF + ATV
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 4897.3
SecondaryPart 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · log10 copies/mL
Part 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 24
log10 copies/mLPart 2 E/C/F/TAF + ATV
Part 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 24-2.96 ± 0.754
SecondaryPart 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · log10 copies/mL
Part 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 48
log10 copies/mLPart 2 E/C/F/TAF + ATV
Part 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 48-3.04 ± 0.594
SecondaryPart 2: Change From Baseline in CD4+ Cell Count at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · cells/μL
Part 2: Change From Baseline in CD4+ Cell Count at Week 24
cells/μLPart 2 E/C/F/TAF + ATV
Part 2: Change From Baseline in CD4+ Cell Count at Week 2476 ± 92.8
SecondaryPart 2: Change From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/μL
Part 2: Change From Baseline in CD4+ Cell Count at Week 48
cells/μLPart 2 E/C/F/TAF + ATV
Part 2: Change From Baseline in CD4+ Cell Count at Week 48125 ± 109.0
SecondaryPart 2: Change From Baseline in CD4+ Percentage at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · percentage change
Part 2: Change From Baseline in CD4+ Percentage at Week 24
percentage changePart 2 E/C/F/TAF + ATV
Part 2: Change From Baseline in CD4+ Percentage at Week 244.4 ± 2.35
SecondaryPart 2: Change From Baseline in CD4+ Percentage at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · percentage change
Part 2: Change From Baseline in CD4+ Percentage at Week 48
percentage changePart 2 E/C/F/TAF + ATV
Part 2: Change From Baseline in CD4+ Percentage at Week 485.7 ± 2.99

Adverse events

Collected over Baseline up to the last dose date plus 30 days (average exposure: Part 1 = 10 days; Part 2 = 86.5 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 Sentinel Cohort TAF0/12 (0%)0/12 (0%)7/12 (58.3%)
Part 1 Randomized Cohort TAF0/28 (0%)3/28 (10.7%)6/28 (21.4%)
Part 1 Randomized Cohort Placebo0/15 (0%)0/15 (0%)5/15 (33.3%)
Part 2 E/C/F/TAF + ATV0/37 (0%)4/37 (10.8%)26/37 (70.3%)
Most frequent serious events
Most frequent serious events
EventPart 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort PlaceboPart 2 E/C/F/TAF + ATV
HypoglycaemiaMetabolism and nutrition disorders0/121/280/150/37
MyopathyMusculoskeletal and connective tissue disorders0/121/280/150/37
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/121/280/150/37
Enlarged uvulaGastrointestinal disorders0/120/280/151/37
HyperbilirubinaemiaHepatobiliary disorders0/120/280/151/37
AngioedemaSkin and subcutaneous tissue disorders0/120/280/151/37
HypotensionVascular disorders0/120/280/151/37
Most frequent other events
Showing 10 of 39
Most frequent other events
EventPart 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort PlaceboPart 2 E/C/F/TAF + ATV
Upper respiratory tract infectionInfections and infestations0/121/280/1511/37
NauseaGastrointestinal disorders2/121/280/150/37
MalariaInfections and infestations0/120/280/155/37
HeadacheNervous system disorders0/120/280/154/37
DiarrhoeaGastrointestinal disorders1/120/280/152/37
HaemorrhoidsGastrointestinal disorders1/120/280/150/37
ProctalgiaGastrointestinal disorders1/120/280/150/37
PyrexiaGeneral disorders1/120/280/152/37
Oral candidiasisInfections and infestations1/120/280/151/37
Urinary tract infectionInfections and infestations1/120/280/152/37

Baseline characteristics

Full Analysis Set: participants who enrolled into Part 1 of the study and received at least one dose of study drug in Part 1.

Age, Continuous
Age, Continuous(years)Part 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort PlaceboTotal
Mean38 ± 7.340 ± 9.143 ± 8.240 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort PlaceboTotal
Female316423
Male9121132
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort PlaceboTotal
Hispanic or Latino5016
Not Hispanic or Latino7281449
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort PlaceboTotal
Asian05510
Black322934
White4105
Other5016
Region of Enrollment
Region of Enrollment(participants)Part 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort PlaceboTotal
Russian Federation2103
United States5308
Dominican Republic5016
Uganda019928
Thailand05510
HIV-1 RNA
HIV-1 RNA(log10 copies/mL)Part 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort PlaceboTotal
Mean4.18 ± 0.6484.16 ± 0.5444.03 ± 0.9534.13 ± 0.688
HIV-1 RNA Category
HIV-1 RNA Category(Participants)Part 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort PlaceboTotal
≤ 100,000 copies/mL12271251
> 100,000 to ≤ 400,000 copies/mL0134
CD4 Cell Count
CD4 Cell Count(cells/µL)Part 1 Sentinel Cohort TAFPart 1 Randomized Cohort TAFPart 1 Randomized Cohort PlaceboTotal
Mean269 ± 207.1245 ± 244.6232 ± 162.4246 ± 213.7

1 further baseline measures are reported on the registry.

09

Study locations

15 sites
  • Midway Immunology and Research center
    Fort Pierce, Florida 34982, United States
  • Triple O Research Institute, P.A.
    West Palm Beach, Florida 33401, United States
  • Rowan Tree Medical, P.A.
    Wilton Manors, Florida 33305, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Penn Presbyterian Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Salvador B Gautier Hospital - Infectious Diseases Department
    Santo Domingo, 10514, Dominican Republic
  • Instituto Dominicano de Estudio Virologicos - IDEV
    Santo Domingo, Dominican Republic
  • Regional state budget health agency Krasnoyarsk Regional Center for Prevention and Control of AIDS
    Krasnoyarsk, 660049, Russian Federation
  • Center For Prevention and Treatment of AIDS and Infectious Diseases, Saint Petersburg
    Saint Petersburg, 190020, Russian Federation
  • The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
    Bangkok, 10330, Thailand
  • Ramathibodi Hospital, Mahidol University
    Bangkok, 10400, Thailand
  • Siriraj Hospital Department of Preventive and Social Medicine, Faculty of Medicine
    Bangkok, 10700, Thailand
  • Chiang Mai University
    Chiang Mai, 50200, Thailand
  • Khon Kaen University
    Khon Kaen, 40002, Thailand
  • Joint Clinical Research Centre
    Kampala, Uganda
10

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

No publications or documents are linked to this record.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in May 2015, 18 months.

Results were first posted in Jun 2017, 2 years after primary completion.

Of 34 industry-sponsored phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's 18 months is below that.

Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 19 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2013
First posted
Oct 23, 2013
StartActual
Oct 25, 2013
Primary completionActual
May 21, 2015
CompletionActual
Jul 31, 2017
Results first posted
Jun 12, 2017
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01967940
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 23, 2013
Start date
Oct 25, 2013
Primary completion
May 21, 2015
Completion
Jul 31, 2017
Results posted
Jun 12, 2017
Last update
Nov 16, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tenofovir alafenamide · Elvitegravir · Cobicistat · Emtricitabine · Atazanavir

Start the discussion